AC Immune SA (ACIU)
NASDAQ
$2.52−$0.1400 (−5.26%) on the dayAs of the close; data may be delayed.
ACIU price, last 12 months
Key stats
- Previous close
- $2.66
- Open
- $2.66
- Day range
- $2.45 – $2.66
- 52-week range
- $2.10 – $4.00
- Volume
- 323.6K
- Avg volume (20 days)
- 159.9K
- Market cap
- $250.6M
Performance
1W−4.2%
1M−11.6%
3M−1.6%
6M−12.8%
YTD−19.8%
1Y−7.7%
vs S&P 500, 1Y−24.5 pts
Technicals and fundamentals
About AC Immune SA
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
- Listed on
- NASDAQ
- Market cap
- $250.6M